Literatur Xerostomie
Bensadoun RJ (2000) Management of Radiation-Induced Xerostomia. Opinions on Topics in Supportive Care in Oncology 4; 3-5
Bohuslavizki KH, Klutmann S, Bleckmann C, Brenner W, Lassmann S, Mester J, Henze E, Clausen M (1999) Salivary Gland Protection by Amifostine in High-Dose Radioiodine Therapy of Differentiated Thyroid Cancer. Strahlentherapie und Onkologie 175; 57-61
Burlage FR, Coppes RP, Meertens H, Stokman MA, Vissink A (2001) Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiotherapy and Oncology 61, 271-274
Capizzi RL, Oster W (1995) Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer 31A S1; 8-13
Chao C, Majhail N, Huang C, Simpson JR, Perez CA, Haughey B, Spector G (2001) Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques, Radiotherapy and Oncology, 61, 275-280
Dawson L, Anzai Y, Marsh L, Martel MK, Paulino A, Ship JA, Eisbruch A (2000) Patterns of Local-Regional Recurrence Following Parotid-Sparing Conformal and Segmental Intensity-Modulated Radiotherapy For head and Neck Cancer. Int J Radiat Oncol Biol Phys Vol 46/5, 1117-1126
Grötz KA, Henneicke Z, Kohnen R, Al-Nawas B, Bockisch A, Kutzner J, Wüstenberg A, Naser-Hijazi B, Belz GG, Wagner W (1999) Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf-Hals-Karzinomen. Strahlentherapie und Onkologie 175/8, 397-403
Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Xerostomia: New Pespectives. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5; 281-288
Hensley ML, Schuchter LM, Lindley C; Meropol NJ., Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Mitchell RB, Negrin R, Szatrowski TP, Thigpen T, vHoff D, Wassermann TH, Winer EP, Pfister DG., for the American Society of Clinical Oncology (1999) American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. Journal of Clinical Oncology 17/10, 3333-3355
Horiot JC, Lipinski F, Schaub S, Maulard-Dudux C, Bensadoun RJ, Ardiet JM, Bourdin S, Wilbault P, Alfonsi M, Calais G, Desprez P, Pene F, Lapeyre M, Vinke J, Maral J (2000) Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiotherapie and Oncology 55, 233-239
Hospers GAP, Eisenhauer EA, de Vries EGE (1999) The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. British J of Cancer, 80, 629-638
Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulias V (2000) Subcutaneous Administration of Amifostine During Fractionated Radiotherapy. J Clin. Oncol., 18/11, 2226-2233
Jellema AP, Langendijk H, Bergenhenegouwen L, van der Reijden W, Leemans R, Smeele L, Slotman BJ (2001) The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiotherapy and Oncology 59, 157-160
Joensuu H (1994) Treatment for post-irradiation xerostomia, New Eng J of Med 330/2, 141-142
Johnson JT, Ferretti GA, Nethery WJ, Valdez ICH, Fox PC, Ng D, Muscoplat CC, Gallagher SC (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. New Eng J Med 329; 390-395
Kusler DL, Rambur BA (1992) Treatment for radiation-induced xerostomia. An innovative remedy. Cancer Nurs 15/3; 191-95
LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, Gallagher SC, Muscoplat CC (1993) A multicenter randomized double blind placebo-controlled dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. JCO 11/6; 1124-131
Lindegaard JC, Grau C (2000) Has the outlook improved for amifostine as a clinical radioprotector? Radiotherapy and Oncology 57, 113-11
Phillips KA, Tannock IF(1998) Design and Interpretation of Clinical Trials That Evaluate Agents That May Offer Protection From the Toxic Effects of Cancer Chemotherapy. J of Clin Oncology 16/9, 3179-3190
Schilstra C, Meertens H (1999) Calculation of the uncertainly in complication probability for various dose-response models, applied to the parotid gland. Clin Investigation 50/1, 147-158
Scott P, Tannehill M, Mehta M (1996) Amifostine and Radiation Therapy: Past, Present, and Future, Seminars in Oncology 23/Suppl 8, 69-77
Strnad V, Wannemacher M, Britzel D, Henke M, Jones C, Eschwege F, Rudat V, Sauer R (1998) Randomized Phase III Trial of Radiation +/- Amifostine in Patients with head and Neck Cancer. Strahlentherapie Onkologie 174/S 1; 5-103
Taylor SE, Miller EG (1999) Preemptive Pharmacologic Intervention in Radiation-Induced Salivary Dysfunction. Society for Experimental Biology and Medicine, 14-26
Trog D, Bank P, Wendt TG, Koscielny S, Beleites E (1999) Daily Amifostine Given Concomitantly to Chemoradiation in Head and Neck Cancer. Strahlentherapie und Onkologie 175/9, 444-9
Zimmermann RP, Mark RJ, Tran LM, Juillard GF (1997) Concomitant Pilocarpine During Head And Neck Irradiation Is Associated With Decreased Posttreatment Xerostomia, Int J Radiation Oncol Biol Phys 37/3, 571-575
|
